Nuclear expression and clinical significance of phosphohistidine phosphatase 1 in clear-cell renal cell carcinoma.

about

Nuclear expression and clinical significance of phosphohistidine phosphatase 1 in clear-cell renal cell carcinoma.

Item

http://www.wikidata.org/entity/Q50962688

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Nuclear expression and clinica ...... ear-cell renal cell carcinoma.

@en

Nuclear expression and clinica ...... ear-cell renal cell carcinoma.

@nl

type

Item

label

Nuclear expression and clinica ...... ear-cell renal cell carcinoma.

@en

Nuclear expression and clinica ...... ear-cell renal cell carcinoma.

@nl

prefLabel

Nuclear expression and clinica ...... ear-cell renal cell carcinoma.

@en

Nuclear expression and clinica ...... ear-cell renal cell carcinoma.

@nl

P1476

Nuclear expression and clinica ...... ear-cell renal cell carcinoma.

@en

P2093

Hongliang Shen

http://www.w3.org/2001/XMLSchema#string

Peiqian Yang

http://www.w3.org/2001/XMLSchema#string

Qingjun Liu

http://www.w3.org/2001/XMLSchema#string

Ye Tian

http://www.w3.org/2001/XMLSchema#string

P2860

14-kDa phosphohistidine phosphatase and its role in human lung cancer cell migration and invasion

Protein histidine phosphatase 1 negatively regulates CD4 T cells by inhibiting the K+ channel KCa3.1

Cancer statistics, 2013

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

Identification and characterization of a mammalian 14-kDa phosphohistidine phosphatase.

Hereditary renal cancer syndromes: an update of a systematic review.

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.

Focus on phosphohistidine.

P304

747-757

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0300060515587576

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-11-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

283512095

http://www.w3.org/2001/XMLSchema#string

P698

26537769

http://www.w3.org/2001/XMLSchema#string